Merck Pharmaceutical Revolutionises Thyroid Health In Nigeria With Euthyrox

Merck Pharmaceutical has launched Euthyrox (levothyroxine sodium) to revolutionise thyroid health in the country.

The launch held recently in Lagos, marks a significant milestone in the company’s commitment to improving thyroid health and providing innovative solutions to patients in Nigeria.

Established in Germany over 356 years ago, Merck has a presence in 66 countries worldwide and is renowned for its advancements in drug formulations. However, the introduction of Euthyrox, used for the treatment and prevention of thyroid disorders, underscores Merck’s dedication to enhancing patient care and addressing unmet medical needs.

This is the first time the medical product makes its way into the Nigerian market as the country joins over 100 other countries in its adoption, after receiving approval from the National Agency for Food and Drug Administration and Control (NAFDAC).

Euthyrox is a well-established treatment for hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone. This medication is designed to restore hormonal balance, thereby alleviating symptoms such as fatigue, weight gain, and depression.

With the introduction of Euthyrox in Nigeria, Merck Pharmaceutical aims to enhance the quality of life for countless individuals affected by thyroid disorders.

Speaking at the launch, Consultant Endocrinologist from the UK, Professor Salman Razvi, provided insights into the clinical benefits of Euthyrox and its impact on thyroid health through his well-thought-through presentation., Country Manager, Merck West Africa, Charles Ajibo emphasised the company’s dedication to addressing the unmet medical needs of patients in Nigeria.

The Country manager, West Africa, Charles Ajibo, maintained that, “We are thrilled to bring Euthyrox to Nigeria, a country where there is a growing need for effective thyroid treatments. Our mission at Merck Pharmaceutical is to improve lives by providing high-quality medications, and the launch of Euthyrox is a testament to this commitment.”

Charles, who is the managing director of Merck Pharmaceutical Nigeria. added that, “Euthyrox has been a trusted treatment for hypothyroidism worldwide, and its availability in Nigeria will be a game-changer for patients who have struggled with thyroid imbalances. We are excited to see the positive impact this will have on public health.”